Abstract:
:Over the past few decades, monoclonal antibodies (mAbs) have become one of the most important and fastest growing classes of therapeutic molecules, with applications in a wide variety of disease areas. As such, understanding of the determinants of mAb pharmacokinetic (PK) processes (absorption, distribution, metabolism, and elimination) is crucial in developing safe and efficacious therapeutics. In the present review, we discuss the use of physiologically-based pharmacokinetic (PBPK) models as an approach to characterize the in vivo behavior of mAbs, in the context of the key PK processes that should be considered in these models. Additionally, we discuss current and potential future applications of PBPK in the drug discovery and development timeline for mAbs, spanning from identification of potential target molecules to prediction of potential drug-drug interactions. Finally, we conclude with a discussion of currently available PBPK models for mAbs that could be implemented in the drug development process.
journal_name
Drug Metab Pharmacokinetjournal_title
Drug metabolism and pharmacokineticsauthors
Glassman PM,Balthasar JPdoi
10.1016/j.dmpk.2018.11.002subject
Has Abstractpub_date
2019-02-01 00:00:00pages
3-13issue
1eissn
1347-4367issn
1880-0920pii
S1347-4367(18)30133-2journal_volume
34pub_type
杂志文章,评审abstract::To investigate the transport function of the blood-brain barrier (BBB), we employed an in vitro model of the BBB, consisting of a co-culture of porcine brain capillary endothelial cells (BCECs) with rat astrocytes. Porcine BCECs were cultured on a filter insert with rat astrocytes on the underlying plastic well. Rat a...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.17.34
更新日期:2002-01-01 00:00:00
abstract::Cytochrome P450 (P450) constitutes a superfamily of enzymes which activate dioxygen and carry out monooxygenation reactions of large numbers of endogenous and xenobiotic compounds. Drug metabolism is a particularly important P450 function, and, therefore, elucidating the metabolic products and pathways of drugs is ess...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.2133/dmpk.20.1
更新日期:2005-02-01 00:00:00
abstract::In this study, we aimed to understand the gap in coverage of pharmacogenomic (PGx) biomarkers between Japan and the US. PGx biomarkers (1) in the Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines; (2) that are CPIC level A or B; or (3) have US Food and Drug Administration (FDA)-approved drug labels...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.08.006
更新日期:2018-12-01 00:00:00
abstract:UNLABELLED:Better prediction of drug disposition prior to the clinical trial is critical for the efficient development of new drugs. The purpose of this study is to develop a novel multiple assessment methodology of hepatocellular drug disposition from drug uptake to efflux including biliary and basolateral excretion, ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2015.12.001
更新日期:2016-04-01 00:00:00
abstract::The injectable form of oxycodone contains hydrocotarnine that is supposed to potentiate the analgesic effect of oxycodone with unknown mechanism(s). In this study, the effects of hydrocotarnine on the cytochrome P450 (CYP) and P-glycoprotein (P-gp) were investigated. Hydrocotarnine did not induce a significant change ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.24.108
更新日期:2009-01-01 00:00:00
abstract::Studies of the genetic regulation involved in drug metabolizing enzymes and drug transporters are of great interest to understand the molecular mechanisms of drug response and toxic events. Recent reports have revealed that hydrophobic ligands and several nuclear receptors are involved in the induction or down-regulat...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.2133/dmpk.21.437
更新日期:2006-12-01 00:00:00
abstract::Chemotherapy-induced neutropenia is one of the major adverse events which results in the reduction of chemotherapy. Doxorubicin is a substrate of the adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) transporter; reportedly, ABCB1 polymorphisms influence doxorubicin pharmacokinetics. We evaluated th...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2014.09.009
更新日期:2015-04-01 00:00:00
abstract::Pitavastatin undergoes little hepatic metabolism but it is a substrate for uptake and efflux transporters, particularly OATP1B1 (gene SLCO1B1). A previous study in 8 Japanese healthy subjects showed that co-administration with grapefruit juice (GFJ) resulted in a small increase in systemic exposure to pitavastatin. We...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,随机对照试验
doi:10.2133/dmpk.dmpk-12-rg-067
更新日期:2013-01-01 00:00:00
abstract::UDP-glucuronosyltransferases (UGTs) catalyze the glucuronidation of a wide variety of xeno/endobiotics. Previous studies have reported that human UGT enzymes are phosphorylated and that treatment of cells with protein kinase C (PKC) inhibitors results in decreased UGT activities without affecting the UGT protein level...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.DMPK-10-RG-121
更新日期:2011-06-01 00:00:00
abstract::Specific antibody production is an important issue in crossover pharmacokinetic (PK) studies of protein-based formulations. We recently reported that intravenous co-administration of tacrolimus with multiple human interferon-alpha (h-IFN) administrations successfully suppressed the production of anti-h-IFN antibodies ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.25.149
更新日期:2010-01-01 00:00:00
abstract::We have recently found that the frequency of OATP-C*15 is significantly higher in patients who experienced myopathy after receiving pravastatin or atorvastatin than in patients without myopathy. However, there were two patients who experienced pravastatin-induced myopathy despite the fact that they did not possess OAT...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.19.453
更新日期:2004-12-01 00:00:00
abstract::Nifedipine is one of drugs that have been suggested to undergo significant first-pass metabolism by cytochrome P450 (CYP) 3A in the intestine, based mainly on pharmacokinetic analyses of in vivo observations. To further substantiate this suggestion, we examined the metabolic extraction of nifedipine from the rat small...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.17.546
更新日期:2002-01-01 00:00:00
abstract::The present study aims is to investigate the metabolic mechanism of Xue-Fu-Zhu-Yu decoction (XFZYD) in the treatment of blood-stasis syndrome in Coronary Heart Disease (CHD). To that end, 30 CHD patients with Blood-Stasis Syndrome (BSS) and 20 healthy subjects were enrolled. LC-Q-TOF/MS analysis determined that in com...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2019.07.004
更新日期:2019-10-01 00:00:00
abstract::Medication therapy is the first line of treatment in the management of epilepsy. Fetal exposure to valproic acid (VPA), an antiepileptic drug, poses an elevated risk of teratogenicity in early pregnancy. Some studies have reported that monocarboxylate transporters (MCTs) may be involved in the placental transport of V...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.03.004
更新日期:2018-12-01 00:00:00
abstract::Decitabine (DAC), a DNA methylation inhibitor, is transported into cancer cells mainly via equilibrative nucleoside transporter 1 (ENT1) and subsequently phosphorylated by deoxycytidine kinase (dCK). We previously reported that apparent DAC uptake into cells may be described using a simple compartment model with clear...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2019.10.002
更新日期:2020-02-01 00:00:00
abstract::The participation of cytochrome P-450 (CYP) isoforms in the metabolism of selegiline was investigated. Experiments using recombinant CYP isoforms expressed in human lymphoblastoid cells showed CYP2B6 to be the major CYP isoform involved with the metabolism of selegiline. CYP1A2 and CYP3A4 also contributed to the metab...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.17.199
更新日期:2002-01-01 00:00:00
abstract::Genetic factors have a significant impact on the PK variability of EFV, much higher than other non-genetic factors, such as demography. In this work we have performed a comprehensive PG analysis of genes encoding the major metabolizing enzymes and transporters of EFV, establishing a clear relationship between the PK p...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2016.06.001
更新日期:2016-10-01 00:00:00
abstract::In the present study, we identified three novel single nucleotide polymorphisms (SNPs), 147C>T in exon 2 (silent), 602G>C in exon 3 (Arg201Pro), and 1134C>T in exon 4 (silent), in the gene of bile acid CoA: amino acid N-acyltransferase (BAAT) by resequencing the entire coding region and the exon-intron junctions of 10...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.22.125
更新日期:2007-04-01 00:00:00
abstract::The interaction between cytochrome P450s (CYP, P450) and UDP-glucuronosyltransferases (UGTs) was studied by co-immunoprecipitation. P450 isoform-selective antibody was used as a probe to co-precipitate UGTs with the P450s from solubilized rat liver microsomes. Antibodies toward CYP3A2, CYP2B2, CYP2C11/13 and CYP1A2 co...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.22.367
更新日期:2007-10-01 00:00:00
abstract::Polymorphic distributions of pharmacogenes among some ethnicities are under-represented in current pharmacogenetic research. Particularly, there is a paucity of pharmacogenetic information in the Sherpa population in Tibet. We used the Sequenom MassARRAY single nucleotide polymorphism (SNP) genotyping technology to de...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2015.11.007
更新日期:2016-02-01 00:00:00
abstract::Clinical studies have revealed that some fluoroquinolones may cause severe adverse effects when co-administered with substrates of CYP1A2. Our previous study showed antofloxacin (ATFX) was responsible for mechanism-based inhibition (MBI) of the metabolism of phenacetin in rats. In the clinical setting, ATFX is likely ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.dmpk-10-rg-126
更新日期:2011-01-01 00:00:00
abstract::Prothrombin time (PT) has been widely used for measuring anticoagulation intensity under rivaroxaban therapy, but precise information has not been well established yet. Consecutive 96 non-valvular atrial fibrillation (NVAF) under rivaroxaban between Jan/June, 2015 were recruited. Serum concentration (SC) and PT with 5...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2018.02.002
更新日期:2018-08-01 00:00:00
abstract::Tuftsin, a natural phagocytosis-stimulating tetrapeptide, had aroused much interest in tumor immunotherapy, but the poor pharmacokinetics hampered its clinical developments, for that it was extremely susceptible to degradation by enzymolysis in vivo. T Peptide (TP) was a newly designed tuftsin derivative aimed to enha...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2015.08.005
更新日期:2016-02-01 00:00:00
abstract::Human OATP2B1, a member of organic anion transporting polypeptide family, is expressed in several tissues, including small intestine and liver, and contributes to cellular uptake of endogenous compounds and various drugs. Altered expression of OATP2B1 affects pharmacokinetics of substrate drugs; however, limited infor...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2020.07.007
更新日期:2020-12-01 00:00:00
abstract::Bioavailability and therapeutic outcome of treatment with HIV-protease inhibitors depends on intestinal and hepatic transporter-enzyme interplay. Liver transport of HIV protease inhibitors (saquinavir, darunavir) was assessed in the presence of aged garlic extract, because the HIV-infected often consume garlic supplem...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.25.307
更新日期:2010-01-01 00:00:00
abstract::Twenty genetic variations, including seven novel ones, were found in the human SLC22A1 gene, which encodes organic cation transporter 1, from 116 Japanese individuals. The novel variations were as follows: -94C>A in the 5'-untranslated region (A of the translation start codon is numbered +1 in the cDNA sequence; MPJ6_...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.19.308
更新日期:2004-08-01 00:00:00
abstract::Nevirapine (NVP) is widely used as a non-nucleoside reverse transcriptase inhibitor of HIV-1, however, it is associated with severe skin and liver injury. The mechanisms of these adverse reactions are not yet clear, but the metabolic activation of NVP is thought to be related to the injury process. Until now, several ...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2020.01.006
更新日期:2020-04-01 00:00:00
abstract::MCT1(SLC16A1) is the first member of the monocarboxylate transporter (MCT) and its family is involved in the transportation of metabolically important monocarboxylates such as lactate, pyruvate, acetate and ketone bodies. This study identifies genetic variations in SLC16A1 in the ethnic Chinese group of the Singaporea...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.2133/dmpk.24.469
更新日期:2009-01-01 00:00:00
abstract::Nrf2 plays a central role in the response to xenobiotics and oxidative stress. The activation of Nrf2 induces the expression of drug-metabolizing enzymes (DMEs) and is important for cytoprotection. Keap1 is a widely accepted proteasome-dependent regulator of Nrf2. Keap1 was reported to be absent in Caenorhabditis eleg...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章
doi:10.1016/j.dmpk.2020.06.007
更新日期:2020-10-01 00:00:00
abstract::Nuclear receptors constitutive active/androstane receptor (CAR) and pregnane X receptor (PXR) were originally characterized as transcription factors regulating the hepatic genes that encode drug metabolizing enzymes. Recent works have now revealed that these nuclear receptors also play the critical roles in modulating...
journal_title:Drug metabolism and pharmacokinetics
pub_type: 杂志文章,评审
doi:10.2133/dmpk.23.8
更新日期:2008-01-01 00:00:00